A Phase 4 interventional study of Celecoxib and Any commercially available NSAID with the indication for osteoarthritis in Osteoarthritis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 777 sites in 2 countries. Open to participants aged 55 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.
Among the 14 studies testing celecoxib in Osteoarthritis, this one has the largest enrollment, is one of 3 that started in 2006, is one of 10 in phase 4, and was the 7th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 55 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,067 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 150 across the 14 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 5 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dosing as per USPI label
Drug: Celecoxib
Drug: Any commercially available NSAID with the indication for osteoarthritis
open-label
dosing as per USPI label related to the chosen commercially marketed NSAID
Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)
CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin.
Time frame: Baseline through week 24 or Early Termination (ET)
Percentage of Participants With Moderate to Severe Abdominal Symptoms
Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms"; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function.
Time frame: Baseline through week 24 or ET
Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)
GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions
Time frame: Baseline through week 24 or ET
Hemoglobin (Hb) at Baseline
Time frame: Baseline
Change From Baseline Hb at Week 24
Time frame: Baseline and Week 24 or ET
Hematocrit (Hct) at Baseline
Time frame: Baseline
Change From Baseline Hct at Week 24
Time frame: Baseline and Week 24 or ET
Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline
Clinically significant decrease in Hct (greater than or equal to 10 percent \[≥10%\]) and/or decrease in Hb (≥ 2 g/dL).
Time frame: Baseline, Weeks 8, 16, 24 or ET
Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall
Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5).
Time frame: Baseline, Weeks 8, 16, 24 or ET
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
Time frame: Baseline, Weeks 8, 16, 24 or ET
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
Time frame: Baseline, Weeks 8, 16, 24 or ET
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
Time frame: Baseline, Weeks 8, 16, 24 or ET
Percentage of Participants With Positive Blood Fecal Occult
Positive blood fecal occult; blood in feces that is not visibly apparent
Time frame: Week 24 or ET
Percentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization
PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists \[H2RA\], misoprostol, sucralfate, and others such as antacids) utilization.
Time frame: Baseline through week 24 or ET
Percentage of Participants With Non-study Medication Utilization
Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use.
Time frame: Baseline through week 24 or ET
| Milestone | Celecoxib | nsNSAIDs |
|---|---|---|
| Started | 4035 | 4032 |
| Treated | 3984 | 3955 |
| Completed | 2596 | 2611 |
| Not completed | 1439 | 1421 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Adverse event | 278 | 253 |
| Withdrew: Insufficient clinical response | 169 | 119 |
| Withdrew: Did not meet entrance criteria | 167 | 184 |
| Withdrew: Lost to follow up | 83 | 103 |
| Withdrew: No longer willing to participate | 337 | 352 |
| Withdrew: Other | 149 | 146 |
| Withdrew: Protocol violation | 191 | 182 |
| Withdrew: Final status unknown | 12 | 4 |
| Withdrew: Randomized, not treated | 51 | 77 |
CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 1.3 | 2.4 |
Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms"; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Percentage of Participants With Moderate to Severe Abdominal Symptoms | 2.3 | 3.4 |
GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs) | 2.8 | 3.0 |
| gram per deciliter (g/dL) | Celecoxib | nsNSAIDs |
|---|---|---|
| Hemoglobin (Hb) at Baseline | 13.6 ± 1.1 | 13.6 ± 1.2 |
| g/dL | Celecoxib | nsNSAIDs |
|---|---|---|
| Change From Baseline Hb at Week 24 | -0.109 ± 0.012 | -0.241 ± 0.012 |
| Percent | Celecoxib | nsNSAIDs |
|---|---|---|
| Hematocrit (Hct) at Baseline | 40.8 ± 3.4 | 40.9 ± 3.4 |
| Percent | Celecoxib | nsNSAIDs |
|---|---|---|
| Change From Baseline Hct at Week 24 | -0.330 ± 0.038 | -0.716 ± 0.039 |
Clinically significant decrease in Hct (greater than or equal to 10 percent \[≥10%\]) and/or decrease in Hb (≥ 2 g/dL).
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Week 8 (n= 3043, 3086) | 0.7 | 0.9 |
| Week 16 (n=2687, 2675) | 0.8 | 1.6 |
| Week 24 (n=3278, 3207) | 0.9 | 1.5 |
| Week 24 LOCF (n=3604, 3574) | 1.8 | 2.9 |
Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5).
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Baseline (n=3887, 3904) | 39.8 | 38.0 |
| Week 8 (n=3181, 3199) | 78.5 | 69.5 |
| Week 16 (n=2784, 2772) | 81.9 | 74.6 |
| Week 24 or ET (n=3383, 3361) | 74.6 | 70.8 |
| Week 24/LOCF (n=3672, 3651) | 74.5 | 70.3 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Baseline (n=3890, 3905) | 43.2 | 43.7 |
| Week 8 (n=3185, 3202) | 80.2 | 71.6 |
| Week 16 (n=2784,2777) | 83.2 | 77.7 |
| Week 24 or ET (n=3386,3362) | 76.2 | 73.8 |
| Week 24/LOCF (n=3672, 3653) | 76.0 | 73.3 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Baseline (n=3888, 3905) | 41.4 | 40.5 |
| Week 8 (n=3185, 3203) | 77.4 | 69.2 |
| Week 16 (n=2783, 2778) | 80.5 | 74.5 |
| Week 24 or ET (n=3385, 3362) | 74.0 | 71.3 |
| Week 24/LOCF (n=3671, 3653) | 74.0 | 70.8 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Baseline (n=3886, 3905) | 37.8 | 36.6 |
| Week 8 (n=3182, 3202) | 75.4 | 66.8 |
| Week 16 (n=2780,2778) | 77.8 | 71.6 |
| Week 24 or ET (n=3383,3361) | 72.2 | 68.8 |
| Week 24/LOCF (n=3671, 3653) | 72.2 | 68.2 |
Positive blood fecal occult; blood in feces that is not visibly apparent
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Percentage of Participants With Positive Blood Fecal Occult | 1.1 | 1.4 |
PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists \[H2RA\], misoprostol, sucralfate, and others such as antacids) utilization.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| PPIs | 23.0 | 24.2 |
| H2RAs | 5.0 | 5.7 |
| Gastric protective agents | 0.9 | 1.0 |
Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use.
| Percentage of participants | Celecoxib | nsNSAIDs |
|---|---|---|
| Acetaminophen | 6.8 | 6.5 |
| Acetylsalicylic acid (ASA) | 3.5 | 3.0 |
| NSAIDs | 12.8 | 13.3 |
| Opioids | 14.2 | 15.6 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 99/3,970 (2.5%) | 962/3,970 (24.2%) |
| nsNSAIDs | — | 95/3,951 (2.4%) | 1,163/3,951 (29.4%) |
| Event | Celecoxib | nsNSAIDs |
|---|---|---|
| Chest painGeneral disorders | 10/3970 | 7/3951 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/3970 | 3/3951 |
| PneumoniaInfections and infestations | 5/3970 | 3/3951 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 5/3970 | 2/3951 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/3970 | 2/3951 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/3970 | 1/3951 |
| AppendicitisInfections and infestations | 0/3970 | 3/3951 |
| DiverticulitisInfections and infestations | 3/3970 | 3/3951 |
| Back painMusculoskeletal and connective tissue disorders | 1/3970 | 3/3951 |
| ParaesthesiaNervous system disorders | 0/3970 | 3/3951 |
| Event | Celecoxib | nsNSAIDs |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 84/3970 | 115/3951 |
| NauseaGastrointestinal disorders | 65/3970 | 112/3951 |
| Upper respiratory tract infectionInfections and infestations | 112/3970 | 75/3951 |
| DyspepsiaGastrointestinal disorders | 65/3970 | 98/3951 |
| SinusitisInfections and infestations | 75/3970 | 88/3951 |
| BronchitisInfections and infestations | 86/3970 | 77/3951 |
| Haemoglobin decreasedInvestigations | 59/3970 | 84/3951 |
| HeadacheNervous system disorders | 67/3970 | 83/3951 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 82/3970 | 73/3951 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 29/3970 | 78/3951 |
| Age, Customized(Participants) | Celecoxib | nsNSAIDs | Total |
|---|---|---|---|
| <55 years | 5 | 2 | 7 |
| 55-59 years | 1339 | 1361 | 2700 |
| 60-64 years | 1149 | 1127 | 2276 |
| 65-69 years | 848 | 822 | 1670 |
| 70-74 years | 504 | 517 | 1021 |
| >=75 years | 184 | 197 | 381 |
| Unspecified | 6 | 6 | 12 |
| Sex/Gender, Customized(Participants) | Celecoxib | nsNSAIDs | Total |
|---|---|---|---|
| Male | 980 | 962 | 1942 |
| Female | 3049 | 3064 | 6113 |
| Unspecified | 6 | 6 | 12 |
Showing the first 100 of 777 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →